About KAICO
KAICO is a company based in Fukuoka (Japan) founded in 2018.. KAICO has raised $4.37 million across 4 funding rounds from investors including Sojitz, Tokyo Century and FFG Venture Business Partners. KAICO offers products and services including Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and Supplements. KAICO operates in a competitive market with competitors including Qkine, Core Biogenesis, Future Fields, Protera and Algenex, among others.
- Headquarter Fukuoka, Japan
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Kaico Ltd.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4.37 M (USD)
in 4 rounds
-
Latest Funding Round
$1.96 M (USD), Series A
Jan 19, 2024
-
Investors
Sojitz
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KAICO
KAICO offers a comprehensive portfolio of products and services, including Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and Supplements. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Offers custom protein production using silkworm system for research.
Provides tailored protein expression services for client needs.
Delivers trial protein expression to test feasibility.
Supplies reagents derived from silkworm-expressed proteins.
Develops supplements using recombinant proteins for various uses.
Creates veterinary and human vaccines via protein expression.
Funding Insights of KAICO
KAICO has successfully raised a total of $4.37M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $1.96 million completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series A — $2.0M
- First Round First Round
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2024 | Amount | Series A - KAICO | Valuation | Tokyo Century , ITOCHU Technology Ventures | |
| Dec, 2021 | Amount | Series A - KAICO | Valuation |
investors |
|
| May, 2020 | Amount | Series A - KAICO | Valuation | FFG Venture Business Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in KAICO
KAICO has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Sojitz, Tokyo Century and FFG Venture Business Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in early-stage startups
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by KAICO
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - KAICO
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Kaico Comparisons
Competitors of KAICO
KAICO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Qkine, Core Biogenesis, Future Fields, Protera and Algenex, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Animal-free growth factors are developed for life science applications.
|
|
| domain | founded_year | HQ Location |
UBaaS platform for plant-based recombinant protein bioproduction is offered.
|
|
| domain | founded_year | HQ Location |
Serum-free bioactive growth factors and recombinant proteins are biomanufactured.
|
|
| domain | founded_year | HQ Location |
Protein-based enzyme technologies are developed using deep learning algorithms.
|
|
| domain | founded_year | HQ Location |
Developer of recombinant biologics for animal and human health
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about KAICO
When was KAICO founded?
KAICO was founded in 2018.
Where is KAICO located?
KAICO is headquartered in Fukuoka, Japan. It is registered at Fukuoka, Fukuoka, Japan.
Who is the current CEO of KAICO?
Kenta Yamato is the current CEO of KAICO.
Is KAICO a funded company?
KAICO is a funded company, having raised a total of $4.37M across 4 funding rounds to date. The company's 1st funding round was a Series A of $2.41M, raised on Oct 01, 2018.
What does KAICO do?
KAICO was founded in 2018 and is based in Fukuoka, Japan, within the biotechnology sector. A portfolio of proteins, cytokines, and enzymes is produced using a silkworm-baculovirus expression system as the primary technology. These products serve applications in medicine and diagnostic reagents. Contract research services for protein expression are also provided, alongside specific items such as PNGase-F, bFGF, and NucA.
Who are the top competitors of KAICO?
KAICO's top competitors include Future Fields, Qkine and Core Biogenesis.
What products or services does KAICO offer?
KAICO offers Protein Expression Service, Custom Protein Expression, Trial Services, Research Reagents, and 2 more products and services.
Who are KAICO's investors?
KAICO has 5 investors. Key investors include Sojitz, Tokyo Century, FFG Venture Business Partners, ITOCHU Technology Ventures, and Mizuho Capital.